Correction of Lysozyme Content in Mixed Saliva in Patients With Jaw Ameloblastomas

Natalia O. Ushkoa more
a Natalia O. Ushko

Associate Professor of Maxillofacial Surgery Department of Shupyk National Medical Academy of Postgraduate Education (PhD, Assoc Prof)

December 28, 2017

https://doi.org/10.23999/j.dtomp.2017.3-4.9

J Diagn Treat Oral Maxillofac Pathol 2017;1:164−7.

Under a Creative Commons license

How to cite this article

Ushko NO. Correction of lysozyme content in mixed saliva in patients with jaw ameloblastomas. J Diagn Treat Oral Maxillofac Pathol 2017;1(3−4):164−7.

ABSTRACT

Purpose: Determine the content of lysozyme in mixed saliva in patients with ameloblastomas of the jaws in the dynamics of the treatment, as well as the effectiveness of using the drug Lysobact for immunocorrection.

 

Material and Methods: 31 patients with ameloblastomas of the jaws were examined in the dynamics of the treatment and in the rehabilitation period.

 

Results: A decrease in local non-specific resistance of the body (studied by the content of lysozyme in mixed saliva) in patients with jaw ameloblastomas during hospitalization and after surgical treatment was established. The purpose of the drug Lysobact allowed normalizing the level of lysozyme content in the mixed saliva of these patients in the rehabilitation period.

 

Conclusions: The use of the drug Lysobact for 2 weeks in patients with ameloblastomas of the jaws allows to completely normalizing the local nonspecific resistance of the organism and significantly reduces the number of inflammatory complications.